Jolanda Paolini

5.6k total citations · 4 hit papers
30 papers, 3.9k citations indexed

About

Jolanda Paolini is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Jolanda Paolini has authored 30 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 6 papers in Genetics. Recurrent topics in Jolanda Paolini's work include Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Diagnosis and Treatment (11 papers) and Lung Cancer Research Studies (11 papers). Jolanda Paolini is often cited by papers focused on Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Diagnosis and Treatment (11 papers) and Lung Cancer Research Studies (11 papers). Jolanda Paolini collaborates with scholars based in United States, Italy and China. Jolanda Paolini's co-authors include Yi‐Long Wu, Tiziana Usari, Keith D. Wilner, Tony Mok, Benjamin Solomon, Enriqueta Felip, Kazuhiko Nakagawa, Fiona Blackhall, Tarek Mekhail and Federico Cappuzzo and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Jolanda Paolini

29 papers receiving 3.9k citations

Hit Papers

First-Line Crizotinib versus Chemotherapy in ALK-Positive... 2014 2026 2018 2022 2014 2018 2018 2024 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
    2014 2.3k citations Benjamin Solomon, Tony Mok et al. New England Journal of Medicine profile →
  2. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer
    2018 285 citations Benjamin Solomon, Dong‐Wan Kim et al. Journal of Clinical Oncology profile →
  3. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer
    2018 225 citations Yi‐Long Wu, James Chih‐Hsin Yang et al. Journal of Clinical Oncology profile →
  4. Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
    2024 118 citations Benjamin Solomon, Geoffrey Liu et al. Journal of Clinical Oncology profile →

Peers

Jolanda Paolini
Gladys Urbanowitz United States
J. Thaddeus Beck United States
Sofia Paul United States
Giorgio Massimini Italy
Haji Chalchal Canada
D. Amoroso Italy
W. Kwasny Austria
David Lorente Spain
Saby George United States
Gladys Urbanowitz United States
Jolanda Paolini
Citations per year, relative to Jolanda Paolini Jolanda Paolini (= 1×) peers Gladys Urbanowitz

Countries citing papers authored by Jolanda Paolini

Since Specialization
Citations

This map shows the geographic impact of Jolanda Paolini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jolanda Paolini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jolanda Paolini more than expected).

Fields of papers citing papers by Jolanda Paolini

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jolanda Paolini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jolanda Paolini. The network helps show where Jolanda Paolini may publish in the future.

Co-authorship network of co-authors of Jolanda Paolini

This figure shows the co-authorship network connecting the top 25 collaborators of Jolanda Paolini. A scholar is included among the top collaborators of Jolanda Paolini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jolanda Paolini. Jolanda Paolini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Solomon, Benjamin, Geoffrey Liu, Enriqueta Felip, et al.. (2024). Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. Journal of Clinical Oncology. 42(29). 3400–3409. 118 indexed citations breakdown →
2.
Solomon, Benjamin, Geoffrey Liu, Enriqueta Felip, et al.. (2024). Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer. Future Oncology. 20(40). 3377–3387.
3.
Solomon, Benjamin, Geoffrey Liu, Enriqueta Felip, et al.. (2024). Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.. Journal of Clinical Oncology. 42(17_suppl). LBA8503–LBA8503. 1 indexed citations
4.
Wu, Yi‐Long, Shun Lü, James Chih‐Hsin Yang, et al.. (2022). Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC. JTO Clinical and Research Reports. 3(10). 100406–100406. 12 indexed citations
5.
Soria, Jean‐Charles, Steffan N. Ho, Marileila Varella‐Garcia, et al.. (2018). Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer. Annals of Oncology. 29(9). 1964–1971. 12 indexed citations
6.
Solomon, Benjamin, Dong‐Wan Kim, Yi‐Long Wu, et al.. (2018). Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 36(22). 2251–2258. 285 indexed citations breakdown →
7.
Gambacorti‐Passerini, Carlo, Sergey Orlov, Li Zhang, et al.. (2018). Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study. American Journal of Hematology. 93(5). 607–614. 74 indexed citations
8.
Goto, Kōichi, Dong‐Wan Kim, Shun Lü, et al.. (2017). Phase II study of Crizotinib in East Asian patients (pts) with ROS1+ advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 28. ix91–ix91. 1 indexed citations
9.
Nishio, Makoto, Dong‐Wan Kim, Yi‐Long Wu, et al.. (2017). Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer. Cancer Research and Treatment. 50(3). 691–700. 45 indexed citations
10.
Mok, Tony, Dongwook Kim, Yi‐Long Wu, et al.. (2017). Overall survival (OS) for first-line crizotinib versus chemotherapy in ALK+ lung cancer: Updated results from PROFILE 1014. Annals of Oncology. 28. v637–v637. 12 indexed citations
11.
Goto, Kōichi, James Chih‐Hsin Yang, Dong‐Wan Kim, et al.. (2016). Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 34(15_suppl). 9022–9022. 16 indexed citations
12.
Solomon, Benjamin, Federico Cappuzzo, Enriqueta Felip, et al.. (2015). Intracranial efficacy of first-line crizotinib vs. chemotherapy in ALK-positive NSCLC. Journal of Thoracic Oncology. 1 indexed citations
13.
Hecht, J. Randolph, Edith Mitchell, Takayuki Yoshino, et al.. (2015). 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study. Cancer Management and Research. 7. 165–165. 9 indexed citations
14.
Solomon, Benjamin, Tony Mok, Dong‐Wan Kim, et al.. (2014). First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. New England Journal of Medicine. 371(23). 2167–2177. 2327 indexed citations breakdown →
15.
16.
17.
18.
Yardley, Denise A., E. Claire Dees, Steve Myers, et al.. (2012). Phase II open-label study of sunitinib in patients with advanced breast cancer. Breast Cancer Research and Treatment. 136(3). 759–767. 21 indexed citations
19.
Geisler, Jürgen, Per Eystein Lønning, Lars Erik Krag, et al.. (2006). Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study. European Journal of Cancer. 42(17). 2968–2975. 84 indexed citations
20.
Bajetta, Emilio, Nicoletta Zilembo, Cristina Noberasco, et al.. (1997). The minimal effective exemestane dose for endocrine activity in advanced breast cancer. European Journal of Cancer. 33(4). 587–591. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gladys Urbanowitz Breakdown of academic impact, for papers by J. Thaddeus Beck Breakdown of academic impact, for papers by Sofia Paul Breakdown of academic impact, for papers by Giorgio Massimini Breakdown of academic impact, for papers by Haji Chalchal Breakdown of academic impact, for papers by D. Amoroso Breakdown of academic impact, for papers by W. Kwasny Breakdown of academic impact, for papers by David Lorente Breakdown of academic impact, for papers by Saby George
Rankless by CCL
2026